alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Honorable Zollie Steakley 

Secretary of State 

Capitol Station 

Austin, Texas 

Opinion No. WW - 562 

Re: Authority of the Secretary 

of State to accept and file 

Articles of Incorporation 

which contain a stated purpose clause and related 

questions. 

Dear Mr. Steakley: 

You have inquired concerning whether a charter should be,:filed 

containing the following purpose clause: 

“To eel1 prearranged or prepaid funeral services 

or funeral merchandise (including caskets, grave 

vaults, and all other articles of merchandise incidental to a funeral service) in this state under a sales 

contract providing for prepaid burial or funeral benefits or merchandise to be’delivered at an undetermined 

future date dependent upon the death of the contracting 

party”. 

I respectfully direct your attention to Opinion of Attorney 

General Mann No. o-2736 written by Ardell Williams. I think this opinion 

in its answer to the third question there discussed will resolve the 

problem with which you are concerned. As I understand your question, your 

office feels that you may be precluded from filing this charter because 

the business described within the purpose clause may fall within the purview of Article 14.37 of the Insurance Code, requiring burial associations 

to organize under Chapter 12 of the Insurance Code and be regulated under 

Chapter 14 of that Code. Article 14.37 Is a codification of Section 2’3, 

Senate Bill 135, Acte 46th Legislature. The third question discussed in 

Opinion o-2736 concerns an activity which would be within the purview of 

the proposed purpose clause. That opinion holds that euch an activity is 

not governed by Section 23, Senate Bill 135. However, you must require 

the purpose clause to be amended to add the following restrictive alnguaae: 

“Provided however, that this corporation shall not 

engage in business a8 an insurance company or a8 a 

burial association”. 
Honorable Zollie Steakley, Page 2, NW-562) 

The corporation must, however, comply with Article 548.b, Vernon's Civil 

Statutee. 

Very truly youm, 

WILL WILSON 

Attorney General of Texas 

Wallace P. Finfrock 

Aaeietant Attorney General 

WPF:aw 

APPROVED: 

OPINION coMITJ!EE: 

Geo. P. Blackburn, Chairmen 

Marietta McGregor Payne 

Marvin Thomse 

REVIEWEDF~RT~~EAT~!ORNEY GENEBAL 

BY: 

W. V. Geppert
EXHIBIT 32.1SECTION 1350 CERTIFICATION     I, Julie Smolyansky, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant toSection 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Lifeway Foods, Inc.(the “Company”) on Form 10-QSB/A for three month period ended March 31, 2006:     (1) fully complies with the requirements of section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and     (2) that the information contained in the report fairly presents, in all materialrespects, the financial condition and results of operations of the Company.     This written statement is being furnished to the Securities and Exchange Commission as anexhibit to such Form 10-QSB. A signed original of this written statement required by Section 906has been provided to the Company and will be retained by the Company and furnished to theSecurities and Exchange Commission or its staff upon request.Date:May 14, 2007       /s/ Julie Smolyansky         Julie Smolyansky, Chief Executive Officer,    President, and Director
EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q/A of Biopure Corporation for the quarter ended April 30, 2008, I, Zafiris G. Zafirelis, Chief Executive
Officer, hereby certify, to the best of my knowledge, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that:

1. the Form 10-Q/A for the period ended April 30, 2008, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in the Form 10-Q/A for the period ended April 30, 2008 fairly presents, in all material respects, the financial
condition and results of operations of Biopure Corporation.



|                                
|--------------------------------
|/s/ Zafiris G. Zafirelis        
|Zafiris G. Zafirelis            
|Chairman of the Board, President
|And Chief Executive Officer     

June 18, 2008



31
# C_2015046EN.01005901.xml

| 9.2.2015 | EN | Official Journal of the European Union | C 46/59 |
| --- | --- | --- | --- |

9.2.2015

EN

Official Journal of the European Union

C 46/59

---

Action brought on 3 December 2014 — August Storck v OHIM (Representation of a square-shaped packaging in white and blue)

(Case T-806/14)

(2015/C 046/76)

Language of the case: English

Parties

Parties

Applicant: August Storck KG (Berlin, Germany) (represented by: P. Goldenbaum, I. Rohr, T. Melchert and A. Richter, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM)

Defendant:

Details of the proceedings before OHIM

Details of the proceedings before OHIM

Trade mark at issue: International registration designating the European Union in respect of the figurative mark (Representation of a packaging in the shape of a square) — International registration No 1 169 244 designating the European Union

Trade mark at issue:

o

Contested decision: Decision of the Fifth Board of Appeal of OHIM of 8 September 2014 in Case R 644/2014-5

Contested decision

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the contested decision; |
| --- | --- |

—

Annul the contested decision;

| — | Order OHIM to pay its own costs and those of the applicant. |
| --- | --- |

—

Order OHIM to pay its own costs and those of the applicant.

Plea in law

Plea in law

| — | Infringement of Article 7(1)(b) of Regulation No 207/2009. |
| --- | --- |

—

Infringement of Article 7(1)(b) of Regulation No 207/2009.

---
| (logo) WELLS FARGO | **Commercial Mortgage  Servicing**D1050-084, 8th Floor  401 South Tryon St.  Charlotte, NC 28202  1-800-326-1334 |
|--------------------|------------------------------------------------------------------------------------------------------------------|

 

 

**ANNUAL STATEMENT OFCOMPLIANCE**

 

Reference is hereby made tothat certain Pooling and Servicing Agreement dated as of April 1, 2015, by andamong WELLS FARGO COMMERCIAL MORTGAGE SECURITIES, INC., as Depositor, WELLSFARGO BANK, NATIONAL ASSOCIATION, as Master Servicer, RIALTO CAPITAL ADVISORS,LLC, as Special Servicer, TRIMONT REAL ESTATE ADVISORS, INC, as Trust Advisor,WELLS FARGO BANK, NATIONAL ASSOCIATION, as Certificate Administrator, as TaxAdministrator and as Custodian and WILMINGTON TRUST, NATIONAL ASSOCIATION, asTrustee, with respect to Commercial Mortgage Pass-Through Certificates Series2015-NXS1 (the "Agreement"). Capitalized terms used herein nototherwise defined shall have the meanings assigned in the Agreement.

 

Pursuant to Section 11.12 ofthis Agreement, I, Daniel Bober, Executive Vice President of CommercialMortgage Services do hereby certify that:

 

1. A review of the activitiesof the Master Servicer during the period from January 1, 2016 through December 31,2016 (the “Reporting Period”), and of its performance per the Agreement duringsuch period has been made under my supervision, and

 

2. To the best of myknowledge, based on such review, the Master Servicer, has fulfilled all of itsobligations under this Agreement in all material respects throughout theReporting Period.

 

 

IN WITNESS WHEREOF, theundersigned has executed this Certificate as of the 28th day of February 2017.

 

/s/ Daniel Bober

Daniel Bober

Executive Vice President 

Wells Fargo Bank

  

 

| Wells Fargo Bank, N.A. | (logo) Together we’ll go far |
|------------------------|------------------------------------|
§ 1.101-6 Effective date. ( a ) Except as otherwise provided in paragraph (h)(4) of § 1.101-4, the provisions of section 101 of the Internal Revenue Code of 1954 and §§ 1.101-1, 1.101-2, 1.101-3, and 1.101-4 are applicable only with respect to amounts received by reason of the death of an insured or an employee occurring after August 16, 1954. In the case of such amounts, these sections are applicable even though the receipt of such amounts occurred in a taxable year beginning before January 1, 1954, to which the Internal Revenue Code of 1939 applies.
( b ) Notwithstanding paragraph (a) of this section, for purposes of determining whether a transfer of an interest in a life insurance contract is a reportable policy sale or a payment of death benefits is a payment of reportable death benefits subject to the reporting requirements of section 6050Y and §§ 1.6050Y-1 through 1.6050Y-4, § 1.101-1(b) through (g) apply to reportable policy sales made after December 31, 2018, and to reportable death benefits paid after December 31, 2018. For any other purpose, including for purposes of determining the amount of the proceeds of life insurance contracts payable by reason of death excluded from gross income under section 101, § 1.101-1(b) through (g) apply to amounts paid by reason of the death of the insured under a life insurance contract, or interest therein, transferred after October 31, 2019. However, under section 7805(b)(7), a taxpayer may apply the rules set forth in § 1.101-1(b) through (g) of the final regulations, in their entirety, with respect to all amounts paid by reason of the death of the insured under a life insurance contract, or interest therein, transferred after December 31, 2017, and on or before October 31, 2019.
[T.D. 6500, 25 FR 11402, Nov. 26, 1960, as amended by T.D. 6577, 26 FR 10128, Oct. 28, 1961; T.D. 9849, 84 FR 9233, Mar. 14, 2019; T.D. 9879, 84 FR 58484, Oct. 31, 2019]
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.9 Limitations of exemptions from section 510(k) of the Federal Food, Drug, and Cosmetic Act (the act). The exemption from the requirement of premarket notification (section 510(k) of the act) for a generic type of class I or II device is only to the extent that the device has existing or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of in vitro diagnostic devices, only to the extent that misdiagnosis as a result of using the device would not be associated with high morbidity or mortality. Accordingly, manufacturers of any commercially distributed class I or II device for which FDA has granted an exemption from the requirement of premarket notification must still submit a premarket notification to FDA before introducing or delivering for introduction into interstate commerce for commercial distribution the device when: ( a ) The device is intended for a use different from the intended use of a legally marketed device in that generic type of device; e.g., the device is intended for a different medical purpose, or the device is intended for lay use where the former intended use was by health care professionals only;
( b ) The modified device operates using a different fundamental scientific technology than a legally marketed device in that generic type of device; e.g., a surgical instrument cuts tissue with a laser beam rather than with a sharpened metal blade, or an in vitro diagnostic device detects or identifies infectious agents by using deoxyribonucleic acid (DNA) probe or nucleic acid hybridization technology rather than culture or immunoassay technology; or
( c ) The device is an in vitro device that is intended: ( 1 ) For use in the diagnosis, monitoring, or screening of neoplastic diseases with the exception of immunohistochemical devices;
( 2 ) For use in screening or diagnosis of familial or acquired genetic disorders, including inborn errors of metabolism;
( 3 ) For measuring an analyte that serves as a surrogate marker for screening, diagnosis, or monitoring life-threatening diseases such as acquired immune deficiency syndrome (AIDS), chronic or active hepatitis, tuberculosis, or myocardial infarction or to monitor therapy;
( 4 ) For assessing the risk of cardiovascular diseases;
( 5 ) For use in diabetes management;
( 6 ) For identifying or inferring the identity of a microorganism directly from clinical material;
( 7 ) For detection of antibodies to microorganisms other than immunoglobulin G (IgG) or IgG assays when the results are not qualitative, or are used to determine immunity, or the assay is intended for use in matrices other than serum or plasma;
( 8 ) For noninvasive testing as defined in § 812.3(k) of this chapter; and
( 9 ) For near patient testing (point of care).
[65 FR 2317, Jan. 14, 2000]
Exhibit 32.2



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002



In connection with the Annual Report of
Borqs Technologies, Inc. (the “Company”) on Form 10-K/A for the fiscal year ended December 31, 2017, as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on
the dates indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that to the best of his knowledge:



|1. | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------



|2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------



Date: May 14, 2018



| | /s/ Anthony K. Chan                                            
| | ---------------------------------------------------------------
| | Anthony K. Chan                                                
| | Chief Financial Officer                                        
| | (Principal Financial Officer and 
Principal Accounting Officer)
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.3570 Knee joint femoral (hemi-knee) metallic uncemented prosthesis. ( a ) *Identification.* A knee joint femoral (hemi-knee) metallic uncemented prosthesis is a device made of alloys, such as cobalt-chromium-molybdenum, intended to be implanted to replace part of a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that consist of a femoral component with or without protuberance(s) for the enhancement of fixation and is limited to those prostheses intended for use without bone cement (§ 888.3027).
( b ) *Classification.* Class III.
( c ) *Date PMA or notice of completion of a PDP is required.* A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any knee joint femoral (hemi-knee) metallic uncemented prosthesis that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a knee joint femoral (hemi-knee) metallic uncemented prosthesis that was in commercial distribution before May 28, 1976. Any other knee joint femoral (hemi-knee) metallic uncemented prosthesis shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[52 FR 33702, Sept. 4, 1987, as amended at 61 FR 50710, Sept. 27, 1996]
Exhibit 32.2



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with this Annual Report on Form 10-K of Clipper Realty Inc. (the "Company") for the period ended December 31, 2016, as filed with the Securities and Exchange Commission (the "Report"), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:



1.     The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and



2.     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.





|Date: | March 30, 2017 | Signed: | /s/ Lawrence E. Kreider
|----- | -------------- | ------- | -----------------------
|      |                |         | Lawrence E. Kreider    
|      |                |         | Chief Executive Officer
§ 884.1640 Culdoscope and accessories. ( a ) *Identification.* A culdoscope is a device designed to permit direct viewing of the organs within the peritoneum by a telescopic system introduced into the pelvic cavity through the posterior vaginal fornix. It is used to perform diagnostic and surgical procedures on the female genital organs. This generic type of device may include trocar and cannula, instruments used through an operating channel, scope preheaters, light source and cables, and component parts.
( b ) *Classification.* ( 1 ) Class II (performance standards).
( 2 ) Class I for culdoscope accessories that are not part of a specialized instrument or device delivery system; do not have adapters, connectors, channels, or do not have portals for electrosurgical, laser, or other power sources. Such culdoscope accessory instruments include: lens cleaning brush, biopsy brush, clip applier (without clips), applicator, cannula (without trocar or valves), ligature carrier/needle holder, clamp/hemostat/grasper, curette, instrument guide, ligature passing and knotting instrument, suture needle (without suture), retractor, mechanical (noninflatable), snare, stylet, forceps, dissector, mechanical (noninflatable) scissors, and suction/irrigation probe. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 884.9.
[45 FR 12684, Feb. 26, 1980, as amended at 61 FR 1123, Jan. 16, 1996; 66 FR 38808, July 25, 2001]
1 Pursuant to 5TH CIR. R. 47.5, the court has determined

that this opinion should not be published and is not precedent

except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 99-11233

Summary Calendar

 

FRED L. MICHAELIS

Petitioner - Appellant

v.

BARBARA ROLLINS

Respondent - Appellee

--------------------

Appeal from the United States District Court for the

Norther District of Texas, Abilene

(1:99-CV-187)

--------------------

April 7, 2000

Before SMITH, BARKSDALE, and PARKER, Circuit Judges.

Per Curiam 1:

IT IS ORDERED that appellee’s motion to dismiss appeal is

DENIED. The judgment of the district court dismissing for want of

jurisdiction is AFFIRMED.
[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Page 9006]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3956]


-----------------------------------------------------------------------

SMALL BUSINESS ADMINISTRATION

[Disaster Declaration <greek-i>12040 and <greek-i>12041]


Virginia Disaster <greek-i>VA-00028

AGENCY: U.S. Small Business Administration.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a Notice of the Presidential declaration of a major 
disaster for Public Assistance Only for the Commonwealth of Virginia 
(FEMA-1874-DR), dated 02/16/2010.
    Incident: Severe Winter Storm and Snowstorm.
    Incident Period: 12/18/2009 through 12/20/2009.
    Effective Date: 02/16/2010.
    Physical Loan Application Deadline Date: 04/19/2010.
    Economic Injury (EIDL) Loan Application Deadline Date: 11/16/2010.

ADDRESSES: Submit completed loan applications to: U.S. Small Business 
Administration, Processing and Disbursement Center, 14925 Kingsport 
Road, Fort Worth, TX 76155.

FOR FURTHER INFORMATION CONTACT: A. Escobar, Office of Disaster 
Assistance, U.S. Small Business Administration, 409 3rd Street, SW., 
Suite 6050, Washington, DC 20416.

SUPPLEMENTARY INFORMATION: Notice is hereby given that as a result of 
the President's major disaster declaration on 02/16/2010, Private Non-
Profit organizations that provide essential services of governmental 
nature may file disaster loan applications at the address listed above 
or other locally announced locations.
    The following areas have been determined to be adversely affected 
by the disaster:

Primary Counties: Albemarle, Alexandria City, Alleghany, Amherst, 
Arlington, Augusta, Bath, Bedford, Botetourt, Buchanan, Caroline, 
Charlottesville City, Culpeper, Dickenson, Fairfax, Fairfax City, Falls 
Church City, Grayson, Greene, Hanover, Highland, Lee, Louisa, Madison, 
Manassas City, Manassas Park City, Montgomery, Nelson, Norton City, 
Orange, Page, Prince William, Rockbridge, Russell, Scott, Spotsylvania, 
Stafford, Staunton City, Waynesboro City, Wise.

    The Interest Rates are:

------------------------------------------------------------------------
                                                                 Percent
------------------------------------------------------------------------
For Physical Damage:
  Non-Profit Organizations with Credit Available Elsewhere....     3.625
  Non-Profit Organizations without Credit Available Elsewhere.     3.000
For Economic Injury:
  Non-Profit Organizations without Credit Available Elsewhere.     3.000
------------------------------------------------------------------------

    The number assigned to this disaster for physical damage is 12040B 
and for economic injury is 12041B.
(Catalog of Federal Domestic Assistance Numbers 59002 and 59008)

James E. Rivera,
Associate Administrator for Disaster Assistance.
[FR Doc. 2010-3956 Filed 2-25-10; 8:45 am]
BILLING CODE 8025-01-P
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1840 Simulatan (including crossed cylinder). ( a ) *Identification.* A simulatan (including crossed cylinder) is a device that is a set of pairs of cylinder lenses that provides various equal plus and minus refractive strengths. The lenses are arranged so that the user can exchange the positions of plus and minus cylinder lenses of equal strengths. The device is intended for subjective refraction (refraction in which the patient judges whether a given object is clearly in focus, as the examiner uses different lenses).
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[52 FR 33355, Sept. 2, 1987, as amended at 53 FR 35605, Sept. 14, 1988; 66 FR 38812, July 25, 2001]